Farapulse Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Farapulse Inc. - overview
Established
2012
Location
Menlo Park, CA, US
Primary Industry
Medical Devices & Equipment
About
Farapulse Inc. designs advanced medical technology for the treatment of atrial fibrillation through its innovative FARAPULSE™ Pulsed Field Ablation (PFA) System, enhancing patient outcomes with minimally invasive procedures. Founded in 2012 and headquartered in Menlo Park, US, Farapulse Inc. specializes in developing the FARAPULSE™ Pulsed Field Ablation (PFA) System.
The company was acquired by Boston Scientific Corporation in September 2020 for USD 295. 00 mn. The acquisition represents a strategic move to enhance Boston Scientific's cardiac care portfolio. Allan Zingeler serves as the CEO, bringing valuable leadership to the organization.
Farapulse Inc. offers the FARAPULSE™ Pulsed Field Ablation (PFA) System, targeting atrial fibrillation (AFib) through an innovative procedure that uses quick pulses of electrical energy. This system offers a precise method for correcting irregular heartbeats while minimizing impact on surrounding tissue, thus providing an advanced alternative to traditional ablation methods. The system is marketed globally, with significant availability in North America and Europe, catering to hospitals and cardiac care centers.
The revenue for Farapulse Inc. is primarily derived from the sales of the FARAPULSE system to healthcare providers and institutions. Direct sales to hospitals and clinics form the core of the revenue model, with pricing based on the specific devices and procedures. The FARAPULSE system serves as a key product contributing to the overall revenue stream.
Following the acquisition by Boston Scientific in September 2020, Farapulse Inc. is positioned for growth with plans to enhance its product offerings and expand into new markets. Future product developments are expected to focus on innovative medical technologies that complement the FARAPULSE system. Boston Scientific plans to leverage its global distribution network to penetrate additional markets, particularly in Asia by 2023.
The recent funding from the acquisition will be utilized to support these growth initiatives and product advancements.
Current Investors
MedVenture Associates, F-Prime Capital, Sante Ventures
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment
Website
www.farapulse.com
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.